30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
P. Garrido Lopez(Hospital Universitario Ramón y Cajal), N. Girard(Institut Curie), B.C. Cho(Yonsei University), J. Sabari(NYU Langone Health), A. Spira(Virginia Cancer Specialists), R.E. Sanborn(Providence Portland Medical Center), K. Goto(National Cancer Center Hospital East), J.C-H. Yang(National Taiwan University), J. Curtin(Janssen (United States)), X. Lyu, ao-Jie He(Janssen (United States)), J. Penton(Janssen (United Kingdom)), J. Edwards(Janssen (United Kingdom)), G. Low Massin, Kunjian Xia(Janssen (United States)), M. Chioda(Janssen (United States)), M. Thayu(Janssen (United States)), R.E. Knoblauch(Janssen (United States)), P. Mahadevia(Janssen (United States)), N. Leighl(Princess Margaret Cancer Centre)
Cited by 8Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis